Compare HSBC Holdings plc (HSBC) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
HSBC Holdings plc vs Merck & Co., Inc. — how do they compare? HSBC Holdings plc trades at $104.1 (market cap $353.82B), while Merck & Co., Inc. trades at $133.48 (market cap $321.77B). The key difference: HSBC Holdings plc and Merck & Co., Inc. are close in size by market cap, and HSBC Holdings plc pays the higher dividend (3.63%). Which is the better fit depends on your goals.
| HSBC | MRK | |
|---|---|---|
Market Cap | $353.82B | $321.77B |
Sector | Technology | Health |
52-Week High | $107.86 | $131.84 |
52-Week Low | $63.84 | $77.60 |
Dividend Yield | 3.63% | 2.61% |
Enterprise Value | — | $368.53B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HSBC trades at $104.05, up 0.71% today, with a bullish technical signal from moving averages and a P/E of 14.74. The bank reported strong Q2 2026 results, including a 7% revenue increase and a $1 billion buyback, while maintaining a 34.54% net income margin. Recent news highlights leadership changes and China-related market pressures.
Outlook remains positive due to earnings momentum and shareholder returns, but risks include China regulatory shifts and valuation concerns after a 40% run. Analyst consensus is mixed with 38% buy ratings, suggesting cautious optimism amid growth and external headwinds.
Merck & Co. (MRK) trades at $133.64, up 2.09% today, with a bullish technical signal from moving averages and strong institutional buying interest. The company reported solid earnings beats in recent quarters, with Q3 2026 EPS expected at $2.27. Revenue for 2025 reached $65.01B, and net income was $18.25B, though the P/E ratio of 104.34 suggests high valuation expectations. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline.
Outlook: MRK's growth is supported by strategic acquisitions and a dominant oncology franchise, but risks include high valuation multiples and competitive pressures. The consensus price target of $140.36 implies modest upside, with 68% of analysts rating it a Buy. Investors should monitor execution on the Terns integration and Q3 earnings results for catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About HSBC Holdings plc
HSBC is one of the world's largest banking and financial services organizations. It serves customers worldwide through four global businesses: Retail, Commercial, Global Banking, and Private Banking.
Read more on HSBC →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
